{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T07:57:14Z","timestamp":1785571034976,"version":"3.56.0"},"reference-count":38,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP24K21148"],"award-info":[{"award-number":["JP24K21148"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Diabetes Invest"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims\/Introduction<\/jats:title>\n                    <jats:p>To evaluate whether sodium\u2010glucose cotransporter 2 inhibitor (SGLT2i) initiation is associated with the risk of urinary tract infection (UTI), with upper UTI and genital infection assessed as secondary outcomes, compared with metformin in patients with immune\u2010mediated inflammatory diseases (IMIDs) and type 2 diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>We conducted a target trial emulation using an active\u2010comparator, new\u2010user design with a Japanese hospital\u2010based claims database from 2014 to 2024. Adults with IMIDs and type 2 diabetes who newly initiated an SGLT2i or metformin were included. The primary outcome was UTI; secondary outcomes were upper UTI and genital infection. Hazard ratios (HRs) were estimated using inverse probability of treatment weighting and weighted Cox proportional hazards models. Prespecified subgroup and interaction analyses further evaluated heterogeneity in UTI risk according to concomitant immunosuppressive therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We analyzed 1,845 SGLT2i initiators and 1,499 metformin initiators (mean age 71.8\u2009years; 55.4% female). Compared with metformin initiation, SGLT2i initiation was not associated with increased risks of UTI (HR 1.14, 95% confidence interval [CI] 0.84\u20131.55) or upper UTI (HR 1.28, 95% CI 0.71\u20132.31). Results for UTI were broadly similar across categories of concomitant immunosuppressive therapies, and interaction analyses showed no evidence of effect modification across these strata, including glucocorticoid dose. The risk of genital infection was higher with SGLT2i initiation (HR 2.31, 95% CI 1.16\u20134.63).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among patients with IMIDs and type 2 diabetes, SGLT2i initiation was not associated with increased risks of UTI or upper UTI compared with metformin, although the risk of genital infection was higher.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdi.70343","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T11:11:12Z","timestamp":1779448272000},"page":"1310-1321","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk of urinary tract infection with\n                    <scp>SGLT2<\/scp>\n                    inhibitor initiation in patients with immune\u2010mediated inflammatory diseases and type 2 diabetes: A target trial emulation using a Japanese hospital\u2010based claims database"],"prefix":"10.1111","volume":"17","author":[{"given":"Hiroshi","family":"Tsushima","sequence":"first","affiliation":[{"name":"Department of Internal Medicine and Rheumatology Juntendo University Shizuoka Hospital  Shizuoka Japan"},{"name":"Division of Rheumatology, Department of Medicine Showa Medical University School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Yajima","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Showa Medical University School of Medicine  Tokyo Japan"},{"name":"Department of Rheumatology Research Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital  Kanagawa Japan"},{"name":"Center for Innovative Research for Communities and Clinical Excellence, Fukushima Medical University  Fukushima Japan"},{"name":"Department of Healthcare Epidemiology School of Public Health in the Graduate School of Medicine, Kyoto University  Kyoto Japan"},{"name":"Department of Clinical Epidemiology Graduate School of Medicine, Fukushima Medical University  Fukushima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Nomiyama","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology, and Metabolism Juntendo University Shizuoka Hospital  Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1640-1373","authenticated-orcid":false,"given":"Ryoko","family":"Sakai","sequence":"additional","affiliation":[{"name":"Department of Public Health and Epidemiology Meiji Pharmaceutical University  Kiyose Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2520-9949","authenticated-orcid":false,"given":"Hisashi","family":"Noma","sequence":"additional","affiliation":[{"name":"Department of Interdisciplinary Statistical Mathematics The Institute of Statistical Mathematics  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Katagiri","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Rheumatology Juntendo University Shizuoka Hospital  Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Tamura","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Rheumatology Juntendo University School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2020-001220"},{"key":"e_1_2_9_3_1","first-page":"10","article-title":"Prednisone use, disease activity and the occurrence of hyperglycaemia and diabetes in patients with early rheumatoid arthritis: A 10\u2010year subanalysis of the BeSt study","volume":"10","author":"Pol JA","year":"2024","journal-title":"RMD Open"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221733"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.251"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60407-2"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12038"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(13)70084-6"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-13-65"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2014.912983"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2014.935764"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa1012"},{"key":"e_1_2_9_13_1","volume-title":"Sodium\u2010glucose Cotransporter\u20102 (SGLT2) Inhibitors","author":"US FDA","year":"2018"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-02733-w"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.7326\/M18-3136"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02074-8"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-019-4859-4"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf580"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.43037"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwg231"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.21383"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2025-087179"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/jgf2.367"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwv254"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4067"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3618"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2020.11.010"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.6607"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.8355"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwn164"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-159-4-201308200-00007"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.910"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14353"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-2169"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24984"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-000935"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2025.02.010"},{"key":"e_1_2_9_38_1","first-page":"131","article-title":"SGLT2 inhibitor and urinary tract infection in men at risk for voiding dysfunction: A VigiBase analysis","volume":"12","author":"Qian Z","year":"2025","journal-title":"Urol Pract"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60828-3"}],"container-title":["Journal of Diabetes Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdi.70343","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdi.70343","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdi.70343","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T06:58:18Z","timestamp":1785567498000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdi.70343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1111\/jdi.70343"],"URL":"https:\/\/doi.org\/10.1111\/jdi.70343","archive":["Portico"],"relation":{},"ISSN":["2040-1116","2040-1124"],"issn-type":[{"value":"2040-1116","type":"print"},{"value":"2040-1124","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"2026-03-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}